|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We tried to reveal the in vivo potential of 17β-HSD1-siRNA-based breast cancer therapy.
|
30863015 |
2019 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
The changes in intracellular glucocorticoid metabolism in the pathogenesis of obesity indicate the participation of modulation by 11<i>β</i>-HSD1, which may represent a new therapeutic target for the treatment of diseases such as type 2 diabetes, visceral obesity, or atherosclerosis.
|
31214617 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pharmacokinetic profile of PBRM in rodents, a first selective covalent inhibitor of 17β-HSD1 for breast cancer and endometriosis treatments.
|
29248731 |
2018 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
This indicates that 17β-HSD1 may be involved in oncogenesis by favoring anti-apoptosis pathway in breast cancer cells and correborates with its previously shown role in increasing breast cancer cell proliferation.
|
27544780 |
2017 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
11beta-HSD1 is implicated in the pathogenesis of metabolic syndrome and its dysregulation has been observed in pregnancy-related complications (pre-eclampsia, intrauterine growth restriction).
|
27018008 |
2017 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
The high activity of estrogen activation provides the basis of 17β-HSD1's implication in estrogen-dependent diseases, such as breast cancer, endometriosis and non-small cell lung carcinomas.
|
27102893 |
2016 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we demonstrate the impact of 17β-HSD1 expression on the breast cancer cell proteome and investigate its role in cell migration.
|
22691413 |
2012 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of 11beta-HSD1 in adipose tissue has been associated with obesity and insulin resistance.
|
22384521 |
2012 |
|
Metabolic Syndrome X
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the association of two 11beta-HSD1 gene (HSD11B1) polymorphisms with the metabolic syndrome (MetS) and its characteristics in the Bosnian population.
|
22384521 |
2012 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results strongly support the rationale for inhibiting 17beta-HSD1 in breast cancer therapy to eliminate estrogen activation via the sulfatase pathway while avoiding the deprivation of DHT.
|
20172961 |
2010 |
|
Malignant neoplasm of breast
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that polymorphisms in the 17beta-HSD1 and SHBG genes may modify the association between isoflavone intake and breast cancer risk.
|
20432167 |
2010 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients.
|
20151319 |
2010 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This suggests that up-regulation of 11beta-HSD1 is a consequence, rather than a cause, of obesity.
|
20410231 |
2010 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hence, 11beta-HSD1 acts at the interface of inflammation and obesity and represents an efficient integrator and effector of local inflammatory and metabolic state.
|
20045052 |
2010 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cortisol is released from subcutaneous adipose tissue by 11beta-HSD1 in humans, and increased enzyme expression in obesity is likely to increase local glucocorticoid signaling and contribute to whole-body cortisol regeneration.
|
18852329 |
2009 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
11beta-HSD1 plays a crucial role in the pathogenesis of obesity and controls glucocorticoid actions in inflammation.
|
19088256 |
2009 |
|
Metabolic Syndrome X
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this work was to evaluate 11beta-HSD1 expression in SAT and VAT of obese patients and evaluate its association to metabolic features of metabolic syndrome.
|
18592327 |
2009 |
|
Metabolic Syndrome X
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our findings indicate that polymorphisms and haplotypes in the 11beta-HSD1 gene are not significantly associated with metabolic syndrome in the Japanese population.
|
19535162 |
2009 |
|
Metabolic Syndrome X
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
11Beta-HSD1 activity is an important component of the HPA axis and contributes to the metabolic syndrome and the normal immune response.
|
19837912 |
2009 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blocking adipogenesis with a novel and specific 11beta-HSD1 inhibitor may represent a novel approach to treat obesity in patients with MS.
|
18434359 |
2008 |
|
Obesity
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the activity and reaction direction of adipose 11beta-HSD1 is altered under conditions of oxysterol excess, and could impact upon the pathophysiology of obesity and its complications.
|
18755798 |
2008 |
|
Metabolic Syndrome X
|
0.100 |
Biomarker
|
disease |
BEFREE |
At a pre-receptor level, 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) activates cortisol from cortisone locally within adipose tissue, and inhibition of 11beta-HSD1 in liver and adipose tissue has been proposed as a novel therapy to treat MS by reducing hepatic glucose output and adiposity.
|
18434359 |
2008 |
|
Metabolic Syndrome X
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we examined the effects of multiple humoral factors related to the metabolic syndrome on the transcriptional activity of 11beta-HSD1 gene in hepatocytes in vitro.
|
18313835 |
2008 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Extensive data have been obtained in mice with transgenic over-expression of 11beta-HSD1 in liver and adipocytes, targeted deletion of 11beta-HSD1, and using novel selective 11beta-HSD1 inhibitors; these data support the use of 11beta-HSD1 inhibitors to lower intracellular glucocorticoid levels and treat both obesity and its metabolic complications.
|
17343766 |
2007 |
|
Obesity
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As 11beta-HSD1 expression in lean women was found to be significantly lower than in lean males, the up-regulation associated with obesity may be relatively more devastating in women than in men, and may help explain the higher relative risk of cardiovascular disease in women suffering from the metabolic syndrome.
|
17712112 |
2007 |